Abstract Details

Title Macular Pigment In Multiple Sclerosis

Topic Neuro-ophthalmology/Neuro-otology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 4-002

Objective

To compare macular pigment optical density (MPOD) values in MS patients with a control group using a non-invasive double autofluorescence method.

Background

Recent evidence suggests that retinal changes mirror global CNS alteration in MS, in fact multiple studies have proven the thinning of certain retinal layers (Retinal Nerve Fibre Layer and Ganglion Cell Layer) in this condition. However, there are no studies on Müller cells, that are the main glial cell in the retina. Cone Müller cells, among different functions, transport macular pigment in the retina. Because of that we thought of an indirect way of investigating them through the measurement of the macular pigment.

Design/Methods

This is a prospective non-interventional study. Patients with diagnosed MS and healthy controls were enrolled and everyone had a study-specific eye examination. MPOD was measured with the auto-fluorescence technique using Spectralis HRA and values were recorded at different degrees of eccentricity (peak, 0 °, 0.5 °, 1 °, 2 °). MPOD values were compared using Student's t-test.

Results

49 patients with MS and 51 controls (mean age: 42.5 ± 11.6 and 40.5 ± 13.9 respectively) participated in the study. There was a predominance of females in both groups (69% of MS patients and 74% of controls). Macular pigment values were lower in MS than in healthy controls (0.58 and 0.68 at 0° and 0.62 and 0.70 at peak respectively) with statistically significant values (P < .001 at 0° and P < .05 at peak). At higher degrees of eccentricity the difference was not significant as physiologically MPOD values decrease with distance from the fovea.

Conclusions

There are no data in literature that evaluate MPOD values in MS. Our research is the first describing a reduction of macular pigment. This finding could expand the knowledge on the pathogenesis and could give us a new biomarker for this disease.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Cinzia Cordioli, MD (Centro Sclerosi Multipla Spedali Civili di Br)	Dr. Cordioli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Dr. Cordioli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Cordioli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
	No disclosure on file
	No disclosure on file
Ruggero Capra, MD	Dr. Capra has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��